Determining the effects of insulin Detemir on endogenous secretion of insulin

What Was Tested

This clinical trial paper looks at Insulin Detemir.

A pilot trial was designed to investigate the effects of the long acting insulin Detemir on endogenous insulin secretion, to assess use in early T2D care.

Why It Was Studied

Type 2 diabetes (T2D) is a long-term metabolic disorder.

Provesn metabolic system models are used to identify patient-specific insulin sensitivity and endogenous insulin secretion from clinical data.

Who Took Part

The abstract describes 3 patients taking part.

PubMed indexes the participants as older adults, both men and women.

Post-cardiac surgery patients with early T2D or pre-diabetes based on HbA1c were given a bolus of insulin Detemir on one day, and none on the second day in hospital.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Insulin Detemir study would be practical.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Insulin Detemir, Models, Theoretical and Pilot Projects.

What This Means in Plain Language

The paper is a pilot study of Insulin Detemir in 3 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference), a journal based in United States.

More context: the Insulin Detemir compound page, all human trials.